Canada warns of liver complications from beta-interferon use for MS
Health Canada is warning health-care professionals of the risks of using beta-interferon therapy for the treatment of multiple sclerosis.
Serious liver injury such as hepatitis has been linked to beta-interferon therapy, including three cases of liver failure that required liver transplantation, the department said in a release. Serious liver injury is considered rare, with cases mostly occurring in the early months of therapy but also in patients on therapy beyond one year, it noted.
The department reminded treating physicians they should perform periodic liver function tests, particularly in the early months of therapy, and patients receiving beta-interferon products should be aware of the signs and symptoms of liver injury.